Literature DB >> 11433817

Hypertrophic cardiomyopathy in the elderly: significance of atrial fibrillation.

Y Doi1, H Kitaoka.   

Abstract

BACKGROUND AND OBJECTIVES: Atrial fibrillation (Af) is an important prognostic indicator for clinical deterioration in patients with hypertrophic cardiomyopathy (HCM), particularly in elderly patients, but its significance may vary from unselected to selected populations. This study investigated the risk of Af as a prognostic factor in long-term mortality and morbidity in Japanese patients with HCM at our institution.
METHODS: All fatal and non-fatal cardiovascular events were estimated in 91 patients with HCM (mean age 51 +/- 14 years, 62 men) and follow up continued for 6.7 +/- 4.8 years.
RESULTS: Either chronic or paroxysmal Af documented by standard electrocardiography (ECG) or ambulatory ECG monitoring at diagnosis and during follow-up were included with other clinical features in the survival analysis. Af was documented in 22 patients (24%). They were older than those without Af (57 +/- 10 vs 48 +/- 14 years, p < 0.005) and had larger left atrial dimensions (43 +/- 6 vs 36 +/- 5 mm, p < 0.01). Cardiovascular events occurred in 12 patients with Af (embolic events in five, heart failure in four, and sudden death in three), and in four patients without Af (embolic event in one, and sudden death in three). Death occurred in 10 patients (seven with Af and three without Af); sudden death in six patients (three with Af and three without Af) and four patients died of cerebrovascular embolism (four with Af and none without Af). Cox's regression analysis showed the occurrence of Af was the most useful predictor of cardiovascular death in patients with HCM. The event-free rate was significantly worse in patients with Af than in those without Af (p < 0.0001).
CONCLUSIONS: Af is an important prognostic feature in patients with HCM, which occurs in older patients and in those with left atrial dilation.

Entities:  

Mesh:

Year:  2001        PMID: 11433817

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  14 in total

1.  Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy.

Authors:  C Fielder Camm; A John Camm
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-06

Review 2.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Diagnosis and Considerations for Management.

Authors:  Monica Patten; Simon Pecha; Ali Aydin
Journal:  J Atr Fibrillation       Date:  2018-02-28

Review 3.  Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.

Authors:  Tiffany T S Ye; Qi Zhuang Siah; Benjamin Y Q Tan; Jamie S Y Ho; Nicholas L X Syn; Yao Hao Teo; Yao Neng Teo; James W Yip; Tiong-Cheng Yeo; Weiqin Lin; Raymond C C Wong; Ping Chai; Bernard Chan; Vijay Kumar Sharma; Leonard L L Yeo; Ching-Hui Sia
Journal:  J Thromb Thrombolysis       Date:  2022-10-03       Impact factor: 5.221

Review 4.  Prediction of atrial fibrillation development and progression: Current perspectives.

Authors:  Konstantinos Vlachos; Konstantinos P Letsas; Panagiotis Korantzopoulos; Tong Liu; Stamatis Georgopoulos; Athanasios Bakalakos; Nikolaos Karamichalakis; Sotirios Xydonas; Michael Efremidis; Antonios Sideris
Journal:  World J Cardiol       Date:  2016-03-26

5.  Thromboembolic Outcomes of Different Anticoagulation Strategies for Patients with Atrial Fibrillation in the Setting of Hypertrophic Cardiomyopathy: A Systematic Review.

Authors:  Matthew R Lozier; Alexandra M Sanchez; John J Lee; Elie M Donath; Vicente E Font; Esteban Escolar
Journal:  J Atr Fibrillation       Date:  2019-12-31

6.  Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA).

Authors:  Oliver P Guttmann; Menelaos Pavlou; Constantinos O'Mahony; Lorenzo Monserrat; Aristides Anastasakis; Claudio Rapezzi; Elena Biagini; Juan Ramon Gimeno; Giuseppe Limongelli; Pablo Garcia-Pavia; William J McKenna; Rumana Z Omar; Perry M Elliott
Journal:  Eur J Heart Fail       Date:  2015-07-16       Impact factor: 15.534

7.  Left ventricular remodeling in hypertrophic cardiomyopathy patients with atrial fibrillation.

Authors:  Hongwei Tian; Jingang Cui; Chengzhi Yang; Fenghuan Hu; Jiansong Yuan; Shengwen Liu; Weixian Yang; Xiaowei Jiang; Shubin Qiao
Journal:  BMC Cardiovasc Disord       Date:  2018-11-03       Impact factor: 2.298

8.  Hypertrophic cardiomyopathies requiring more monitoring for less atrial fibrillation-related complications: a clustering analysis based on the French registry on hypertrophic cardiomyopathy (REMY).

Authors:  Marion Hourqueig; Guillaume Bouzille; Albert Hagège; Erwan Donal; Mariana Mirabel; Olivier Huttin; Thibaud Damy; Fabien Labombarda; Jean-Christophe Eicher; Philippe Charron; Gilbert Habib; Patricia Réant
Journal:  Clin Res Cardiol       Date:  2021-05-27       Impact factor: 5.460

9.  Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population.

Authors:  Konstantinos C Siontis; Jeffrey B Geske; Kevin Ong; Rick A Nishimura; Steve R Ommen; Bernard J Gersh
Journal:  J Am Heart Assoc       Date:  2014-06-25       Impact factor: 5.501

10.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Is the Extent of Septal Hypertrophy Important?

Authors:  Kyoung-Min Park; Sung Il Im; Eun Kyoung Kim; Sang-Chol Lee; Seung-Jung Park; June Soo Kim; Young Keun On
Journal:  PLoS One       Date:  2016-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.